{"nctId":"NCT00410761","briefTitle":"An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer","startDateStruct":{"date":"2006-11-30","type":"ACTUAL"},"conditions":["Thyroid Cancer"],"count":437,"armGroups":[{"label":"1","type":"NO_INTERVENTION","interventionNames":[]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: ZD6474 (Vandetanib)"]}],"interventions":[{"name":"ZD6474 (Vandetanib)","otherNames":["ZACTIMAâ„¢","SAR390530"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic Medullary Thyroid Cancer.\n* Presence of measurable tumor\n* Able to swallow medication\n\nExclusion Criteria:\n\n* Major surgery within 4 weeks before randomization\n* Last dose of prior chemotherapy received less than 4 weeks prior to randomization\n* Radiation therapy within the last 4 weeks prior to randomization(with exception of palliative radiotherapy)\n* Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days\n* Significant cardiac events\n* Previous ZD6474 treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival(PFS)","description":"Median time to progression (months) from randomisation until objective disease progression (determined by RECIST assessments) or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment. Values here are estimated (from a Weibull model) as the medians were not met.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.5","spread":null},{"groupId":"OG001","value":"19.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as defined by RECIST criteria.\n\nThe categories for best objective response are CR, PR, stable disease (SD)\\>= 12 weeks, progressive disease (PD) or NE.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR)","description":"Disease control rate is defined as the number of patients who achieved disease control at 8 weeks following randomisation. Disease control at 8 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) \\>= 12 weeks","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"200","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment). Values are estimated as the medians weren't met","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"16.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"As data was immature at data cut off, number of death events is quoted","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Biochemical Response Calcitonin (CTN)","description":"Best biochemical response was calculated from assessments at baseline and during treatment. Responders were those patients with a best biochemical response of CR or PR, confirmed by repeat assessments, which were to be performed no less than 4 weeks after the criteria for PR or CR were first met. CR and PR being defined according to level of CTN.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Biochemical Response Carcinoembryonic Antigen (CEA)","description":"Best biochemical response was calculated from assessments at baseline and during treatment. Responders were those patients with a best biochemical response of CR or PR, confirmed by repeat assessments, which were to be performed no less than 4 weeks after the criteria for PR or CR were first met. CR and PR being defined according to level of CEA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Worsening of Pain (TWP)","description":"TWP was derived using the worst pain score from brief pain inventory (BPI) and patient reported opioid analgesic use. BPI uses 0 to 10 numeric rating scales asking subjects to rate their pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":71,"n":231},"commonTop":["Diarrhoea","Rash","Nausea","Hypertension","Fatigue"]}}}